Gedeon Richter UK has taken over full marketing and distribution rights for the neuropsychiatry treatment Reagila (cariprazine) in the UK following a transfer from Recordati Pharmaceuticals.

Under the terms of the agreement, Gedeon Richter UK assumes responsibility for the promotion of cariprazine in the UK while continuing as the marketing authorisation holder. The product was originally developed by parent company Gedeon Richter and is licensed for the treatment of schizophrenia in adult patients.

Cariprazine forms part of Gedeon Richter’s central nervous system portfolio, an area the company has identified as an important and growing focus. The move brings the UK in line with several other countries, largely in Central and Eastern Europe, where Gedeon Richter markets cariprazine directly through its affiliate network. In other territories, the drug is commercialised via partner companies.

The transfer follows nearly a decade of marketing and distribution by Recordati in the UK. Gedeon Richter UK said the change reflects a strategic decision to bring UK commercialisation of the product in house, allowing the affiliate organisation to manage engagement with healthcare professionals and patients directly.

Remigijus Narauskas, managing director at Gedeon Richter UK and Ireland, highlighted the company’s long-standing involvement in neuropsychiatry research and development. He said: “We are proud of Richter’s heritage in neuropsychiatry and the pivotal role we played in the development of cariprazine, which was first discovered by Richter scientists in the early 2000s.”

Narauskas added: “A strategic decision has been made to bring UK commercialisation of cariprazine to Gedeon Richter UK, and we would like to thank Recordati for its role in leading the marketing and distribution of the drug over the last nine years.”

As part of the transition, Joe Durante has joined Gedeon Richter UK in January 2026, taking on the role of national neuroscience advisor. Durante previously held the same position at Recordati, ensuring continuity of expertise during the handover of responsibilities.

Schizophrenia is a chronic and disabling mental health condition associated with significant long-term impact on patients, families and healthcare systems. Gedeon Richter UK said it remains committed to ensuring uninterrupted access to treatment for patients currently prescribed cariprazine.

David Jordan, medical director at Gedeon Richter UK and Ireland, said the company’s priority is continuity of care. He said: “Schizophrenia is a chronic and disabling disorder that imposes a significant burden on patients and their loved ones. We are committed to improving the quality of life for those suffering from this chronic mental health condition and we are pleased to continue providing cariprazine to eligible patients throughout the UK.”

Patients already receiving cariprazine treatment in the UK will continue to have their medication supplied by Gedeon Richter, with no expected disruption resulting from the transfer of marketing and distribution responsibilities.